Pet cancer therapeutics market

Pet Cancer Therapeutics Market, by Therapy Type (Chemotherapy, Targeted Therapy, Combination Therapy, and Immunotherapy), by Pet Type (Cat, Dog, and Horse), by Mode of Administration (Oral, Intravenous, and Topical), by Application (Lymphoma, Mast Cell Cancer, Melanoma, Mammary and Squamous Cell Cancer, and Others) and by Region - Global Trends, and Forecast till 2025

  • Feb 2018
  • CMI1284
  • 194 Pages
  • Excel & Pdf
  • Pharmaceutical

Pet Cancer Therapeutics Market – Efficient Cancer Cure in Companion Animals

Pet cancer therapeutics are the novel drug molecules that exhibit high potential to reduce the effects of cancer, giving access to comprehensive cancer care with minimum side effects. Cancer therapies aims to permanently eradicate the cancerous cells prevalent in pets. The veterinarian recommends specific treatment program such as targeted therapy and combination therapy or chemotherapy depending on the type of cancer, stage, and nature of the cancer. The ongoing research activities undertaken by the scientists for the development of novel formulations and therapies is expected to accelerate the market growth. For instance, the scientists at University of Veterinary Medicine are currently exploring the molecular basis of cancer progression in canine cell lines, stating that the modern cancer therapy can be revolutionized with the introduction of targeted therapies.

The global pet cancer therapeutics market was valued at US$ 183.3 million in 2017 and is expected to witness a robust CAGR of 7.7% over the forecast period (2017 - 2025).

Figure 1. Global Pet Cancer Therapeutics Market (US$ Mn), by Region, 2017

Source: Coherent Market Insights (2018)

Increasing R&D initiatives for cancer management to augment market growth

Increasing number of research grants to launch various anti-cancer therapies for veterinary cancer treatment is expected to be a major factor driving growth of the global pet cancer therapeutics market in near future. For instance, in 2017, Animal Cancer Foundation (ACF) received a US$ 1 million grant from the Blue Buffalo Foundation to support comparative oncology research, which aimed to study similarities between naturally occurring cancers in people and pets and find effective treatment in both species. Also, in 2016, the Petco Foundation and Blue Buffalo Foundation invested US$ 2.35 million to support pet cancer research and treatment, as it represents a major cause of illness and premature death in affected species worldwide. Moreover, in 2017, Jackson Laboratory launched Tallwood Canine Cancer Research Initiative (TCCRI), to create a biobank of dog tumors for providing insights on cancer cure through research, in order to develop the most effective cancer therapy. Furthermore, organizations such as Animal Cancer Foundation, Petco Foundation, Veterinary Cancer Society, and PetCure Oncology are conducting oncology research such as canine cancer genome project to understand the genetic makeup of cancer tumors in animals, in order to discover targeted drug therapies with least toxic doses. However, increasing adoption of alternative treatment methods such as herbal medications, homeopathy and adverse effects such as diarrhea, musculoskeletal disorder, anorexia and high cost associated with pet cancer treatment are the factors restraining the market growth.

Increasing incidence and remission rates of pet cancers to accelerate the market growth

Increasing prevalence of cancer indicates a need to adopt approved novel therapies, which are proved to be highly effective for the treatment of cancers in pets, thus, augmenting the pet cancer therapeutics market growth during the forecast period. According to the study by Fetch a Cure, 2015, dogs and cats have a higher incidence of tumors than humans, where dogs are 35 times more likely to develop skin cancer, 4 times more likely to develop breast tumors, and 8 times more likely to develop bone cancer. According to the study published by Animal Cancer Foundation, 2017, approximately around 25% of all dogs will develop a tumor at some point in their life. Furthermore, increasing number of relapsed cancer rates and the availability of relapsed/ refractory therapeutics integrated with veterinarian recommendation is expected to additionally generate the revenue for the market players. According to the study by petMD, LLC, 2015, about 95% of dogs treated for lymphoma with chemotherapy protocols and conventional treatments are expected to experience disease relapse or remission. The duration of remission is less than 15 months in 50% of dog species. In 2017, a novel chemotherapy drug named Tanovea-CA1 (rabacfosadine for injection), manufactured by VedDC, Inc. was conditionally approved by the FDA as a first line treatment for dogs to treat relapsed/refractory lymphoma and canine lymphoma. The conditional approval of drug allows manufacturer to legally sell Tanovea-CA1, before proving it meets the substantial evidence standard of effectiveness for full approval.

The major players operating the global pet cancer therapeutics market include Aratana Therapeutics, Inc., AB Science, Boehinger Ingelheim International GmbH, Zenoaq, Morphogenesis, Inc., VetDC, Inc., Karyopharm Therapeutics, Inc., Regeneus Ltd., Rhizen Pharmaceuticals SA, Oasmia Pharmaceuticals AB, and Zoetis.

Table of Contents

  1. Research Objective and Assumption
    • Research Objectives
    • Assumptions
    • Abbreviations
  2. Market Purview
    • Report Description
      • Market Definition and Scope
    • Executive Summary
      • Market Snippet, By Therapy Type
      • Market Snippet, By Pet Type
      • Market Snippet, By Mode of Administration
      • Market Snippet, By Application
      • Market Snippet, By Region
    • Coherent Opportunity Map (COM)
  3. Market Dynamics, Regulations, and Trends Analysis
    • Market Dynamics
      • Drivers
      • Restraints
      • Market Opportunities
    • Key Highlights
    • Pipeline Analysis
    • Regulatory Guidelines
    • Initiatives for Prevention of Pet Cancer
    • Approved Targeted Therapies for Pet Cancer
    • Epidemiology
  4. Global Pet Cancer Therapeutics Market, By Therapy Type, 2017 – 2025, (US$ Million)
    • Introduction
      • Market Share Analysis, 2016 and 2025 (%)
      • Y-o-Y Growth Analysis, 2017 – 2025
      • Segment Trends
    • Chemotherapy
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2017 – 2025, (US$ Million)
    • Targeted Therapy
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2017 – 2025, (US$ Million)
    • Combination Therapy
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2017 – 2025, (US$ Million)
    • Immunotherapy
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2017 – 2025, (US$ Million)
  5. Global Pet Cancer Therapeutics Market, By Pet Type, 2017 – 2025, (US$ Million)
    • Introduction
      • Market Share Analysis, 2016 and 2025 (%)
      • Y-o-Y Growth Analysis, 2017 – 2025
      • Segment Trends
    • Cat
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2017 – 2025, (US$ Million)
    • Dog
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2017 – 2025, (US$ Million)
    • Horse
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2017 – 2025, (US$ Million)
  6. Global Pet Cancer Therapeutics Market, By Mode of Administration, 2017 – 2025, (US$ Million)
    • Introduction
      • Market Share Analysis, 2016 and 2025 (%)
      • Y-o-Y Growth Analysis, 2017 – 2025
      • Segment Trends
    • Oral
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2017 – 2025, (US$ Million)
    • Intravenous
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2017 – 2025, (US$ Million)
    • Topical
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2017 – 2025, (US$ Million)
  7. Global Pet Cancer Therapeutics Market, By Application, 2017 – 2025, (US$ Million)
    • Introduction
      • Market Share Analysis, 2016 and 2025 (%)
      • Y-o-Y Growth Analysis, 2017 – 2025
      • Segment Trends
    • Lymphoma
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2017 – 2025, (US$ Million)
    • Mast Cell Cancer
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2017 – 2025, (US$ Million)
    • Melanoma
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2017 – 2025, (US$ Million)
    • Mammary and Squamous Cell Cancer
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2017 – 2025, (US$ Million)
    • Others
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2017 – 2025, (US$ Million)
  8. Global Pet Cancer Therapeutics Market, By Region, 2017 – 2025, (US$ Million)
    • Introduction
      • Market Share Analysis, By Region, 2016 and 2025 (%)
      • Y-o-Y Growth Analysis, For Regions, 2017 – 2025
    • North America
      • Market Size and Forecast, By Therapy Type, 2017 – 2025, (US$ Million)
      • Market Size and Forecast, By Pet Type, 2017 – 2025, (US$ Million)
      • Market Size and Forecast, By Mode of Administration, 2017 – 2025, (US$ Million)
      • Market Size and Forecast, By Application, 2017 – 2025, (US$ Million)
      • Market Size and Forecast, By Country, 2017 – 2025, (US$ Million)
        • U.S.
        • Canada
    • Latin America
      • Market Size and Forecast, By Therapy Type, 2017 – 2025, (US$ Million)
      • Market Size and Forecast, By Pet Type, 2017 – 2025, (US$ Million)
      • Market Size and Forecast, By Mode of Administration, 2017 – 2025, (US$ Million)
      • Market Size and Forecast, By Application, 2017 – 2025, (US$ Million)
      • Market Size and Forecast, By Country, 2017 – 2025, (US$ Million)
        • Brazil
        • Mexico
        • Argentina
        • Rest of Latin America
    • Europe
      • Market Size and Forecast, By Therapy Type, 2017 – 2025, (US$ Million)
      • Market Size and Forecast, By Pet Type, 2017 – 2025, (US$ Million)
      • Market Size and Forecast, By Mode of Administration, 2017 – 2025, (US$ Million)
      • Market Size and Forecast, By Application, 2017 – 2025, (US$ Million)
      • Market Size and Forecast, By Country, 2017 – 2025, (US$ Million)
        • Germany
        • U.K.
        • France
        • Italy
        • Spain
        • Russia
        • Rest of Europe
    • Asia Pacific
      • Market Size and Forecast, By Therapy Type, 2017 – 2025, (US$ Million)
      • Market Size and Forecast, By Pet Type, 2017 – 2025, (US$ Million)
      • Market Size and Forecast, By Mode of Administration, 2017 – 2025, (US$ Million)
      • Market Size and Forecast, By Application, 2017 – 2025, (US$ Million)
      • Market Size and Forecast, By Country, 2017 – 2025, (US$ Million)
        • China
        • India
        • Japan
        • Australia
        • South Korea
        • ASEAN
        • Rest of APAC
    • Middle East
      • Market Size and Forecast, By Therapy Type, 2017 – 2025, (US$ Million)
      • Market Size and Forecast, By Pet Type, 2017 – 2025, (US$ Million)
      • Market Size and Forecast, By Mode of Administration, 2017 – 2025, (US$ Million)
      • Market Size and Forecast, By Application, 2017 – 2025, (US$ Million)
      • Market Size and Forecast, By Country, 2017 – 2025, (US$ Million)
        • GCC
        • Israel
        • Rest of Middle East
    • Africa
      • Market Size and Forecast, By Therapy Type, 2017 – 2025, (US$ Million)
      • Market Size and Forecast, By Pet Type, 2017 – 2025, (US$ Million)
      • Market Size and Forecast, By Mode of Administration, 2017 – 2025, (US$ Million)
      • Market Size and Forecast, By Application, 2017 – 2025, (US$ Million)
      • Market Size and Forecast, By Country, 2017 – 2025, (US$ Million)
        • South Africa
        • Central Africa
        • North Africa
  9. Competitive Landscape
    • Heat Map Analysis
    • Market Share Analysis (3x3 Matrix)
    • Company Profiles
      • Aratana Therapeutics, Inc.*
        • Company Overview
        • Product Portfolio
        • Financial Performance
        • Recent Developments/Updates
        • Future Plans
      • AB Science
        • Company Overview
        • Product Portfolio
        • Financial Performance
        • Recent Developments/Updates
        • Future Plans
      • Boehringer Ingelheim International GmbH
        • Company Overview
        • Product Portfolio
        • Financial Performance
        • Recent Developments/Updates
        • Future Plans
      • Zenoaq
        •  Company Overview
        • Product Portfolio
        • Financial Performance
        • Recent Developments/Updates
        • Future Plans
      • Morphogenesis, Inc.
        • Company Overview
        • Product Portfolio
        • Financial Performance
        • Recent Developments/Updates
        • Future Plans
      • VetDC, Inc.
        • Company Overview
        • Product Portfolio
        • Financial Performance
        • Recent Developments/Updates
        • Future Plans
      • Karyopharm Therapeutics, Inc.
        • Company Overview
        • Product Portfolio
        • Financial Performance
        • Recent Developments/Updates
        • Future Plans
      • Rhizen Pharmaceuticals SA
        • Company Overview
        • Product Portfolio
        • Financial Performance
        • Recent Developments/Updates
        • Future Plans
      • Regeneus Ltd.
        • Company Overview
        • Product Portfolio
        • Financial Performance
        • Recent Developments/Updates
        • Future Plans
      • Oasmia Pharmaceuticals AB
        • Company Overview
        • Product Portfolio
        • Financial Performance
        • Recent Developments/Updates
        • Future Plans
      • Zoetis
        • Company Overview
        • Product Portfolio
        • Financial Performance
        • Recent Developments/Updates
        • Future Plans
        •  
    • Analyst Views
  10. Section
    • References
    • Research Methodology
    • About us and Sales Contact

*Browse 55 market data tables and 45 figures on "Pet Cancer Therapeutics Market - Global forecast to 2025”.

N/A
- Frequently Asked Questions -

What are the growth estimates for pet cancer therapeutics market till 2025?

The global pet cancer therapeutics market is estimated to surpass US$ 332.6 Million by 2025.

Which are the prominent pet cancer therapeutics market players across the globe?

Major players operating in the global pet cancer therapeutics market include Aratana Therapeutics, Inc., AB Science, Boehinger Ingelheim International GmbH, Zenoaq, Morphogenesis, Inc., VetDC, Inc., Karyopharm Therapeutics, Inc., Regeneus Ltd., Rhizen Pharmaceuticals SA, Oasmia Pharmaceuticals AB, and Zoetis.

What are the key factors hampering growth of the pet cancer therapeutics market?

Increasing adoption of alternative treatment methods such as herbal medications, homeopathyand high cost associated with pet cancer treatment are some of the major factors that are expected to hamper growth of the market over the forecast period.

What are the key factors driving growth of the pet cancer therapeutics market?

Increasing number of research grants to launch various anti-cancer therapies for veterinary cancer treatmentis one of the major factors that is expected to propel growth of the market over the forecast period.

What is the Compound Annual Growth Rate (CAGR) of the pet cancer therapeutics market for next 8 years?

The global pet cancer therapeutics market is estimated to exhibit a CAGR of 7.7% over the forecast period

Which segment based on therapy type, accounted for the highest demand in thepet cancer therapeutics market?

Among therapy type, chemotherapy segment holds a dominant position in the pet cancer therapeutics market, owing to easy availability of the drugs and high recommendation by the veterinary doctors for opting chemotherapy.
© 2024 Coherent Market Insights Pvt Ltd. All Rights Reserved.